[
  {
    "ts": "2026-02-11T05:41:47+00:00",
    "headline": "The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call",
    "summary": "Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing mo",
    "url": "https://finance.yahoo.com/news/top-5-analyst-questions-boston-054147311.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "2c694a08-1aa2-3da8-9418-3b4d2a44d3f1",
      "content": {
        "id": "2c694a08-1aa2-3da8-9418-3b4d2a44d3f1",
        "contentType": "STORY",
        "title": "The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call",
        "description": "",
        "summary": "Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing mo",
        "pubDate": "2026-02-11T05:41:47Z",
        "displayTime": "2026-02-11T05:41:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/6265bcd96c352c9ba8b13bd3600a768f",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BSX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iCi.nqREHmQOxsmCS2lEAw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/6265bcd96c352c9ba8b13bd3600a768f.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k2Icr5R6E7opM7PqWFVWAw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/6265bcd96c352c9ba8b13bd3600a768f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-boston-054147311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-boston-054147311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]